Correction of Psoriatic T Cell Signatures by Deucravacitinib

NCT05858645 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Psoriasis Vulgaris

Interventions

DRUG: deucravacitinib

Sponsor

University of California, San Francisco

Collaborators

[object Object]